Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 3/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21396432 | 0.77 | MAPT (0.37) | MAPTBLMPMP22TSHRNFKB1 | |
| SCHEMBL21396369 | 0.77 | TDP1 (0.40) | — | |
| SCHEMBL21396507 | 0.74 | MAPT (0.31) | MAPTBLMPMP22TSHRNFKB1 | |
| SCHEMBL25929765 | 0.72 | MAPT (0.45) | MAPTBLMPMP22TSHRNFKB1 | |
| SCHEMBL21396418 | 0.71 | MAPT (0.39) | MAPTBLMPMP22TSHRNFKB1 | |
| SCHEMBL21396384 | 0.71 | TLR7 (0.35) | MAPT | |
| SCHEMBL25929055 | 0.70 | MAPT (0.46) | MAPTBLMPMP22TSHRNFKB1 | |
| SCHEMBL25928905 | 0.70 | PDE4A (0.47) | MAPTBLMPMP22TSHRNFKB1 | |
| SCHEMBL25929197 | 0.69 | MAPT (0.44) | MAPTBLMPMP22TSHRNFKB1 | |
| SCHEMBL25928883 | 0.69 | MAPT (0.41) | MAPTBLMPMP22TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PDE7A, PRKG1, PDE4C | MAPT 4419/4885BLM 2555/4885PMP22 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.